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Aims The current challenge in atrial fibrillation (AF) treatment is to develop effective, efficient, and safe ablation strategies. This
randomized controlled trial assesses the medium-term efficacy of duty-cycled radiofrequency ablation via the circular
pulmonary vein ablation catheter (PVAC) vs. conventional electro-anatomically guided wide-area circumferential abla-
tion (WACA).
Methods
and results
One hundred and eighty-eight patients (mean age 62+12 years, 116 M : 72 F) with paroxysmal AF were prospectively
randomized to PVACorWACA strategies and sequentially followed for 12months. The primary endpoint was freedom
from symptomatic or documented.30 s AF off medications for 7 days at 12months post-procedure. One hundred and
eighty-threepatients completed12 m follow-up.Ninety-four patients underwent PVACPV isolationwith 372of 376 pul-
monary veins (PVs) successfully isolated and all PVs isolated in 92WACA patients. ThreeWACA and no PVAC patients
developed tamponade. Fifty-six percent ofWACAand 60%of PVACpatientswere freeof AF at 12months post-proced-
ure (P ¼ ns)with a significant attrition rate from77 to 78%, respectively, at 6months. Themean procedure (140+ 43 vs.
167+42 min, P, 0.0001), fluoroscopy (35+ 16 vs. 42+20 min, P, 0.05) times were significantly shorter for PVAC
than forWACA. Two patients developed strokes within 72 h of the procedure in the PVAC group, one possibly related
directly to PVACablation in a high-risk patient and none in theWACAgroup (P ¼ ns). Twoof the 47 patients in the PVAC
group who underwent repeat ablation had sub-clinical mild PV stenoses of 25–50% and 1 WACA patient developed
delayed severe PV stenosis requiring venoplasty.
Conclusion The pulmonary vein ablation catheter is equivalent in efficacy toWACAwith reduced procedural and fluoroscopy times.
However, there is a risk of thrombo-embolic and pulmonary stenosis complications which needs to be addressed and
prospectively monitored.
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Identiﬁer
NCT00678340.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords Electrophysiology † Ablation † Atrial fibrillation † Duty-cycled bipolar and unipolar radiofrequency
* Corresponding author. Tel: +44 203 456 7898; fax: +44 203 456 4014. E-mail address: pier.lambiase@uclh.nhs.uk
& The Author 2014. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/ .0/), which
permits non-commercial re-use, distribution, and reproduction in anymedium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@
oup.com
Europace (2014) 16, 1145–1153
doi:10.1093/europace/euu064
4
 at U
CL Library Services on Septem
ber 10, 2014
http://europace.oxfordjournals.org/
D
ow
nloaded from
 
Introduction
Radio-frequency energy (RF) ablation utilizing 3D mapping systems
has shown considerable efficacy vs. medical therapy in treating both
paroxysmal and persistent atrial fibrillation (AF).1,2 With this has
come the requirement to simplify and shorten the procedure to
meet the exponential increase in patient demand as demographic
trends predict an epidemic of this condition. The advent of fluorosco-
pically guided ‘one-shot’ ablation technologies, e.g. cryoablation, laser,
RFmultipolarcatheters, offers theopportunity to simplify theproced-
ure and expand the population it is available to. Aswith any new tech-
nology, initial studies tend to be small and are directed to highly
selected patient populations. Although there have been a number
of studies evaluating duty-cycled unipolar and bipolar RF pulmonary
vein (PV) isolation, there have only been two randomized controlled
trials and both did not employ the HRS/EHRA/ECAS consensus
statement recommendation of a 12-month time point in all cases to
evaluate AF burden off drugs and indeed one trial studied a mixed
population of paroxysmal atrial fibrillation (PAF) and persistent
patients.3 This single-blinded multicentre randomized controlled
trial of multipolar ablation technology was designed to evaluate the
efficacy of this technology in four UK centres representative of the
current paroxysmal AF referral patterns in the UK and compare it
with standard 3D mapping-guided wide-area circumferential antral
ablation (WACA).
Methods
The studywasdesignedas aprospective, single-blinded, randomizedmul-
ticentre controlled trial. Ethical approvalwas grantedby theULCHEthics
Committee. All subjects provided informed consent. Paroxysmal AFwas
defined in each patient as self-terminating episodes of documented AF
(on 72 h—7-day Holter) with episodes lasting between ,48 h and
7 days maximum. Patients were randomized and allocated equally
between the standard 3D electroanatomically guided WACA ablation
and PVACutilizing duty-cycled RFenergy delivery (PVAC,MedtronicAb-
lation Frontiers). This is a 9F deflectable circular multielectrode catheter
that enables mapping and circumferential PV ablation.4 The accompany-
ing GENius multichannel, duty-cycled RF generator (Medtronic Ablation
Frontiers) enables the delivery of energy in a unipolar or bipolar
configuration to all electrodes simultaneously or individually. During an
RF application, energy delivery to individual electrodes is temperature
controlled by a software algorithm that modulates power to reach the
user-defined target temperature (maximum 8 W per electrode with
the PVAC in a 4 : 1 power setting or 10 W in all other settings). The
patients were blinded to the catheter used for the duration of the trial.
The endpoints of the trial were:
(i) The differences in procedure times using the circular ablation
(PVAC) catheter when compared with WACA and PVI.
(ii) The efficacy of the circular ablation catheter vs. WACA and PVI
in eliminating paroxysmal AF measured by a 7-day ECG Holter
recording off anti-arrhythmic drugs (AADs) at 12 months following
AF ablation (adjudicated by each centre).
(iii) The safety profile of the techniques for procedural and long-term
complications.
The principal inclusion criteria were patients with paroxysmal AF who
had failed at least one anti-dysrhythmic drug who had been listed for a
planned PVI procedure. Exclusion criteria included patient objection,
prior AF ablation, left atrial size .60 mm, mechanical prosthetic mitral
valve replacement, hypertrophic cardiomyopathy, contraindications to
anticoagulation, pregnancy.
After the informed consent had been obtained, consecutive patients
were randomized to one method for PV isolation: (i) the duty-cycled
bipolar and unipolar RF ablation (PVAC group) or (ii) a point-by-point
antral ablation (WACA group). Anticoagulation with warfarin was
stopped 3 days before admission and bridged with heparin or anticoagu-
lation was maintained to achieve an international normalized ratio (INR)
of 2–3.5 during the course of the procedure andAADs continued until 5
days pre-procedure. Transoesophageal echocardiography was per-
formed in all patients immediately before ablation to exclude left atrial
thrombus. Ablation was performed under conscious sedation or
general anaesthetic. The WACA group had three-dimensional recon-
structions of the left atrium (LA) and PV ostia performed using the
EnSite Verismo software (St. Jude Medical) or CARTO-XP (Biosense
Webster).
All surface electrocardiograms and bipolar intracardiac electrograms
were registered in a BARD digital recording system. Signals were
sampled at 1 kHz, filtered at 0.1–100 Hz for surface electrocardiograms
and at 30–250 Hz for intracardiac signals.
Randomization and blinding
Individual patients were randomized to either PVAC or WACA using
random permuted blocks with equal numbers of patients allocated to
each arm. Treatments were guaranteed to be balanced after a given
block size. The block size chosen was not revealed to the investigators.
A computer generated list of allocations (‘WACA&PVI’ or ‘circular cath-
eter’) was produced by the Medical Statistics Department at UCLH.
These sequential allocations were sealed in envelopes. Each sealed enve-
lope was opened immediately prior to the procedure so patients were
randomly allocated in the order they arrive in the catheter laboratory
for their procedure. The contents of the envelopes were not known to
the investigators.
The 11 attending electrophysiologists performing the procedures
were all experienced operators (in both techniques) undertaking at
least 100AFablations per annumand.5 years experienceofAFablation
and there was no significant difference in their experience between the
treatment groups. The patients were blinded to the catheter used
during the procedure for the duration of the trial. It was not possible
to blind the operators. The persons analysing the Holter data were
blinded to the catheter used. In total 10 patients were recruited from
What’s new?
† This is the onlymulticentre randomized controlled trial of pul-
monary vein ablation catheter (PVAC) vs. standard wide-area
encirclement for PAF following HRS/EHRA/ECAS consensus
statement recommendations on reporting efficacy at 12
months.
† The study confirms equivalent efficacy reported in smaller
cohort and shorter duration studies but demonstrates an im-
portant tail-off in efficacy between 6 and 12 months.
† There was a 2% incidence of stroke in the PVAC ablation arm
which although not statistically significant corroborates con-
cerns frommeta-analysis that measures to prevent this devas-
tating complication need to be undertaken and evaluated
prospectively.
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Southampton, Bournemouth, and Glenfield Heart Centre, respectively,
and the remainder from the Heart Hospital, UCLH.
Pulmonary vein ablation catheter ablation
The technique of PVI isolation using this technique has been described in
detail elsewhere.5 In brief a single trans-septal puncture was performed
using an SL1 sheath and this was exchanged for a Bard 11F channel
sheath to pass the PVAC catheter into the LA following initial pulmonary
venography todefine thePVostia.Abolusofheparin (50–100 IU/kg)was
administeredpost trans-septal puncture and additional heparinwas given
throughout the procedure to maintain the activated clotting time (ACT)
in a specified therapeutic range. The circular decapolar 9 Fr bidirectional
PVACcatheterwas advancedover a 0.032 inchwire,whichwas selective-
ly positioned in each PVor PV branch, using PV angiography to define the
PV ostium. Distal ablation in the PV was avoided and lesions were
targeted in the antral region or at the ostium. Selectively cannulating
specific branches of the veins was especially important to optimize the
catheter–atrial wall contact when isolating large common ostia. With
this single catheter, it was possible to map local signals, to stimulate
and to apply RF over all or selected electrode pairs. Filter settings
at the electrophysiological (EP) workstation were 100–500 Hz. The
PVAC was connected to the GENius (Medtronic, Inc.) RF generator
(Version 11 software Medtronic Ablation Frontiers GENius Multi-
Channel RF Generators (Model Number 990018) were employed until
May 2011 for the first 74 PVAC patients and then the remaining 20
with subsequent software versions (12.2, 14.0–14.4)). It delivered RF
in a combination of one or more of the five bipolar channels. Each elec-
trode was supplied with a thermocouple, which permitted a continuous
local temperature monitoring. The target temperature was 608C with a
maximum power of 8 W. Bipolar/unipolar RF delivery was set in a 4 : 1
ratio, creating a 3 to 4 mm-wide and deep lesion.6 Only exceptionally,
RF ablation was set in a 2 : 1 bipolar/ unipolar proportion, when the
created lesion was estimated to be non-transmural with the 4 : 1
setting. Impulse duration was 60 s. Premature termination of ablation
was generally avoided, and only performed when pain occurred, or the
catheter was dislocated. After several RF applications over all electrode
pairs, individual pairs were activated to ablate any remaining sleeves. In
large veins where contact was poor, some poles were initially switched
off if no signal was recorded. The endpoint was electrical isolation of
the vein (i.e. no PV potentials) confirmed by pacing to demonstrate en-
trance block (with a steerable quadraploar catheter/decapolar catheter
in the CS or LA) placing the PVAC within 1 cm of the ostium to check
the level of isolation (Figure 1). If a vein could not be isolated standard
catheter ablation was not applied.
LUPV Signals per-ablation LUPV Signals post-ablation
A
C
B
Figure1 ExampleofPVACpositioning and signals recorded in LUPVpreandpost ablation. (A) Pulmonary venogram(B) PVACposition in the large
LUPV branch. (C) Unipolar signals recorded pre and post ablation with distal CS pacing illustrating signal attenuation and PV isolation.
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Wide area antral circumferential ablation
The technique for WACA has been described elsewhere with the add-
itional use of a lasso catheter to record PV signals.7 In summary, a
double trans-septal puncture was performed using an SL1 and Agilis
guide sheath and 3D geometry created using the Carto or NAVX
mapping system. Thereafter, an antral point-by-point circumferential
ablation around ipsilateral PVs, with a distance of 0.5–1.0 cm from the
ostia, using a 4 mm open-tip irrigated catheter (IBI Therapy Coolpath
Duo 7 Fr, St Jude Medical Coolflex or Biosense Thermocool) was
performed. Maximum power was set to 30–35 W anteriorly going
selectively up to 40 W if PV isolation could not be achieved and 25–
30 W posteriorly. Temperature was limited to 438C. Irrigation was
adjustedmanually between 17 and 30 mL/min. Complete electrical isola-
tion wasmonitored on the lasso in the PV and confirmed by pacing from
the CS decapolar catheter during sinus rhythm and differential pacing
manoeuvers. Electrical cardioversion was performed if the patient
remained in AF after PV isolation as was the case in the PVAC group.
Anticoagulation
Fourteen patients in the WACA group (mean INR 2.6+ 0.4) and 19
patients in the PVAC group (mean INR 2.3+ 0.4) continued warfarin
for the duration of the procedure. The remainder stopped warfarin
3 days pre-procedure and was placed on therapeutic fragmin such that
their INR on the day of procedure was 1.2–1.5. In the PVAC patients, a
bolus of heparin (50–100 IU/kg) was administered post trans-septal
puncture and additional heparin was given throughout the procedure
to maintain the ACT between 250 and 300 s in patients with an INR of
.2 and .300 s in those who were not anticoagulated with INR . 2.
ACT was checked initially 20 min after the first bolus and then every
30 min once therapeutic. Ablation was commenced once ACT was
.250 s in the warfarinized patients and .300 s in the non-fully warfar-
inized cases. The mean ACTs after the initial ACT during the case were
291+48 s (range 223–370 s) in the PVAC group and 302+43 s
(234–426 s) in theWACAgroup. ForWACApatients, ACTsweremain-
tained with a target of .250 s. Protamine was administered post-
procedure and LMW heparin recommenced (when required) 3–6 h
post-procedure when haemostasis was confirmed.
Procedural data
The number of RF impulses and duration required for completing isola-
tion were recorded in the PVAC group and the total RF time in the
WACA group. Total skin-to-skin procedural time, left atrial dwell time
(time from trans-septal puncture to procedure end), and total fluoros-
copy time were also collected. In-hospital complications were also
recorded.
Follow-up
All patients were maintained on anticoagulants for the first 3 months
post-procedure. These were stopped if the patients were free of AF
and had aCHADSVASc scoreof,2.0. Anti-arrhythmicswere continued
post ablation and stopped routinely at 3 months post-procedure if the
patient was asymptomatic and had no recorded AF. Patients were
reviewed at 3, 6, and 12 months post-procedure with a 72 h Holter.
Holter recordings were also repeated if the patient developed arrhyth-
mia symptoms despite a normal Holter recording at the specified follow-
up times. Serial Holter monitoring for the purpose of the trial was
stopped if AF was documented on resting ECG or Holter. Any patients
still takingAADs for suspected symptomatic but non-documentedAF re-
currence had them stopped at 12 months for the 7-day Holter.
A blanking period of 3monthswas employed.More than 30 s of docu-
mented AF or other atrial tachycardia .3 months post-procedure was
regarded as a failure of PVI during follow-up. The clinic physicians had
access to the patient’s procedural details if required. A decision for
re-ablationwasmade if the patient had documented symptomatic recur-
rences of AF or AT beyond the 3-month blanking period. These patients
were treated as ablation failures for the analysis of 12-month success.
Patients who failed to complete the PV isolation procedure or were
lost to follow-up were censured from the 12-month ablation outcomes
analysis. Therefore, outcomes are presented as on treatment analysis as
opposed to intention to treat.
Statistical analysis
Continuous variables were expressed as mean+ SD. Categorical vari-
ables are expressed as percentage. The x2 and t tests were used for
comparisons between groups, and the Kaplan–Meier curve was used
to compare arrhythmia-free survival between groups. A P value of
,0.05 was considered significant. Pilot data indicated that the standard
deviation of WACA and PVAC procedure time is 30 min. The study
required a sample size of 48 patients in each group to detect a significant
difference (90% power, P ¼ 0.05) in procedure time between techni-
ques. The trialwasdesigned as a non-inferiority study in termsof compar-
ing outcomes for atrial arrhythmia recurrence. If the PVAC ablation
actually has freedom of AF of 70%, it was calculated as 70 patients in
each group to prove non-inferiority (80% power). All authors have
reviewed the data and accepted responsibility for its integrity. The trial
was registered with Clinical Trials.gov-ClinicalTrials.gov Identifier:
NCT00678340.
Results
A total of 188 PAF patients were finally recruited into the trial
between September 2007 and March 2012. The mean age of partici-
pants was 62+12 years (116M : 72 F). The full demographic profile
of the patient treatment arms is shown in Table 1. The patients had
well-preserved ventricular function and no significant valvular heart
disease.
There was a clinically insignificant age difference between the
PVAC and WACA groups. There were no significant differences in
the experience of the physicians performing the procedures in
each arm. The CONSORT diagram (Figure 2) illustrates the
number of patients recruited and follow-up.
Immediate procedural outcomes
A total of 94/94 patients underwent successful PVAC PVI. In total
372/376 PVs were successfully isolated with convincing loss of PV
potentials (common ostia were counted as two veins). In one
patient, it was not possible to isolate a large common left-sided PV
and RIPV and in another one RIPV could not be cannulated due to
extremeangulationof the vein and its small size.Onepatient required
DC cardioversion to sinus rhythm at the end of the procedure.
In theWACAgroup, 92/94 patients achieved electrical isolation of
the PV’s. Three developed cardiac tamponade during ablation and
twoof thesepatients declined furtherAFablation and theothercom-
pleted ablation of all four PV’s byWACA 3 months later. Therefore,
368/376 PV’s were successfully isolated. The former two patients
were censured from follow-up in the WACA group as failures to
isolate. Two patients required DC cardioversion to sinus rhythm at
the end of the procedure.
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The mean ACTs after the initial ACT during the procedures were
298+ 43 s (range 223–426 s) in the PVAC group and 311+43 s
(range 234–364 s) in the WACA group.
Overall procedure times were 16% shorter in the PVAC group
(P, 0.0001) with a 17% shorter LA dwell time, 17% (P, 0.0001)
reduced fluoroscopy time (P, 0.05), and 33% reduced RF time
(P, 0.0001) (Table 2). There were no significant differences in the
total amount of energy delivered between the two approaches
from the data available in 74 PVAC cases and 25 WACA cases
(68 609+29 156 J vs. 55 187 + 32 407 J, P ¼ 0.06).
Complications
In total, therewere six complications. Therewere three cardiac tam-
ponade events during threeWACA cases and zero during the PVAC
(P ¼ ns).Twooccurred soonafter trans-septal puncture, onewith an
NIH catheter manipulation to image the PVs, one during geometry
creation with manipulation of the ablation catheter in the left atrial
appendage, andonedue to steampopduring left-sidedWACAapply-
ing 30 W near the LA roof.
Two strokes occurred in PVAC subjects and none in the WACA.
Both subjects were in sinus rhythm at the start of the case. The
first was a subject who had a previous history of transient ischaemic
attack (TIA) and treated hypertension (CHADSVASC 3). He had
commenced fragmin pre-operatively and stopped warfarin 3 days
before, his pre-op INRwas 1.5. He had a normal pre-operative trans-
esophageal echocardiogram (TEE) and had therapeutic INR’s pre-
procedure with heparin bridging and ACT’s of 250 s initially to
.300 s during the procedure, post-procedural protamine and thera-
peutic LMW heparin as per usual protocol. The following morning
post-procedure, he had a homonymous haemianopia secondary
to an occipital infarct which did not recover. It was not possible
to know the exact timing of this event as he had returned to the
ward sedated that evening and did not notice the field defect until
the next morning.
The second patient developed a right eye inferior quadrant field
defect 2 days post ablation with PVAC—an magnetic resonance
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Demographics
WACA PVAC P value
N 94 94
Age, years (mean) 62+11 58+12 P, 0.05
Male : female (%) 58 : 36 58 : 36
HT (%) 28 24 ns
Diabetes (%) 3 6 ns
Structural heart disease 3 6 ns
Mean ejection fraction 62+11 64+6 ns
Mean LA size (mm) 39+5 38+7 ns
TIA/CVA 2 3 ns
AF frequency
Daily 16 17 –
2–3/week 24 21 –
1/week 17 20 –
1/month 19 17 –
2–3/month 18 19 –
CHADSVASC score
0 28 30 –
1 26 24 –
2 25 19 –
3 11 18 –
4 3 3 –
5 1 0 –
Anti-dysrhythmic drugs (no patients treated)a
Class I 33 34 –
Amiodarone 11 15 –
Sotalol 20 21 –
b-blockers 50 54 –
TIA/CVA, transient ischaemic attack/cerebrovascular accident; HT, hypertension.
aDescribes all drugs employed at any time in any patient.
Decision to have AF ablation 
Discuss participation in trial.
Medical history and consent
Randomisation
N = 188
AF ablation with
WACA and PVI
N  = 94
(2 procedures not
completed due to
tamponade)  
AF ablation with
circular ablation
catheter
N  = 94
(All completed
successfully) 
3 Months after procedure: clinic visit (standard)
discuss symptoms, review medications and 72 hour
Holter N  = 186
6 Months after procedure: clinic visit (standard)
discuss symptoms, review medications and 72 hour
Holter N  = 186
12 Months after procedure: clinic visit (standard)
discuss symptoms, review medications and 7 day Holter
N  = 183
7 day Holter (research)
evaluate  per-procedural AF burden
3 lost to
follow-up
Figure 2 CONSORT diagram illustrating patient recruitment
numbers and follow-up.
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imaging (MRI) confirmed two small infarcts in the fronto-parietal
lobes. He had a normal pre-operative TEE and therapeutic INRs
having stopped warfarin with heparin cover 3 days pre-op with an
INR of 1.2 on the day of procedure. ACT’s during the procedure
had been between 260 and 320 s. His ablation had been unremark-
able but had required DC cardioversion at the end of the case as
he developed AF during catheter manipulation. He received post-
operative protamine. He had been on therapeutic doses of LMW
heparin while recommencing warfarin and had a pre-op CHADS-
VASC score of 0. This field defect did not recover.
Therewasnoprospective strategy to image thePVs forPVstenosis
post-procedure due to cost limitations. Pulmonary vein stenosis was
specifically checked for in patients undergoing repeat procedures.
OneWACA patient developed clinical PV stenosis 12 months post-
procedure.This patient had a geometry shift during ablation requiring
remapping withNAVX and it is likely that RF was inadvertently deliv-
ered too close to the PV common ostium. He had a delayed presen-
tation with increasing exertional dyspnoea 12 months post ablation
requiring venoplasty to the left upper and left lower pulmonary
vein (LU and LLPV). In 2 of the 47 caseswho had a repeat AF ablation
procedure with PV angiography, it was noted that the LUPV had a
mild 40% stenosis in one PVAC case and 50% in another PVAC
case. The latter resulted in a 5 mmHg pressure gradient but since
the patient was not symptomatic, it was not angioplastied. No
WACA patients developed a PV stenosis.
One PVAC patient developed a pseudo-aneurysm 24 h post-
procedure requiring thrombin injection but did not suffer any long-
term sequelae.
Oneyear follow-up arrhythmia recurrence
Data are presented according to treatment analysis. In total, 183
patients completed 12 months full follow-up. Three patients were
lost to follow-up, onedue todeath fromheart failure11monthspost-
procedure, and twowhomoved away and declined further monitor-
ing. Twoof the tamponadepatients declineda repeat procedure.This
means that there were no 12-month follow-up data in 5/188 rando-
mized patients. Overall, 60% of the PVAC patients were free of AF
and atrial arrhythmias off anti-dysrhythmics on 7-day Holter 12
months post ablation. This compares with 56% of the WACA
group at 12 months (Figure 3, Kaplan–Meier curves)(P ¼ ns). It is
interesting to note that there was a minimal difference in success at
6 months—(77% WACA, 78% PVAC) but a further decline out to
12 months. Twenty-four patients in the PVAC group and 23 in the
WACA group required repeat ablation for documented recurrent
symptomatic AF. These patients were treated as ablation failures
for the analysis of 12-month success.
In the PVAC repeat ablation group, 73 of the 96 ablated PV’s had
reconnected and 67 of 92 PV’s in the WACA group (P ¼ ns).
Therewas no evidence of.50%PV re-stenosis in the PVACpatients
on angiography.
Discussion
This is thefirst single-blindedmulticentre randomizedcontrolled trial
to directly compare PVAC ablation with conventional WACA in a
pure PAF population with a definite endpoint of freedom from AF
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Procedural data
WACAmean (range) PVACmean (range) P value
Mean procedure time (min) 167+42 (95–270) 140+43 (70–270) ,0.0001
Left atrial dwell time (min) 133+36 (90–210) 111+35 (55–220) ,0.0001
Fluoroscopy time (min) 42+20 (9–86) 35+16 (4–86) ,0.05
RF application time (min) 40+14 (8–49) 27+8 (13–68) ,0.0001
Mean number of RF applications per vein
PVAC
L. superior PV – 8 –
L. inferior PV – 9 –
Left common PV – 15 –
R. superior PV – 7 –
R. inferior PV – 6 –
R. common PV – 10 –
1.0
0.8
0.6
0.4
0.2
0.0
0 2 4 6 8 10 12
P = ns
Months post procedure
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No of events
WACA
PVAC
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Figure3 Kaplan–Meier curves demonstrating freedomfromAF/
AT post ablation.
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on 7-dayHolter at 12months as advocated by theHRS/EHRA/ECAS
consensus statement.3 Previous studies have either been single-
centre, non-randomized, or investigated mixed populations of PAF
and persistent patients.5,8–15 This trial demonstrates that there are
no significant differences in 1-year long-term outcomes either with
PVACor withWACA. The main differences are borne out by signifi-
cantly shorter procedure and fluoroscopy times in the PVAC group
and lower rates of cardiac tamponade reflecting the different tech-
nical aspects of the respective procedures. However, there was a
2% stroke rate in the PVAC arm.
These data mirror the findings from smaller studies with a high
success rate 75% at 6 months but then a further 50% attrition rate
of recurrence. Furthermore, there is a consistent difference in
37 min reductions in procedure times and shorter fluoroscopy
times with PVAC vs. WACA. The WACA fluoroscopy times are
20 min longer than currently with the greater stability of and con-
fidence in the geometries of current 3Dmapping systems. Therefore,
WACAfluoroscopy timeswouldbeexpected tobeshorter if the trial
was performed from2013; however, PVACfluoroscopy timeswould
remain unchanged. The reported PVAC procedure times and lesion
delivery data in this study are equivalent to that described by experi-
enced centres summarized in a recent systematic review—116.9+
33.4 min, fluoroscopy time was 26.5+9.6 min, and the number of
PVAC applications per patient was 25.1+3.4.16 These time differ-
ences clearly reflect the additional time required to create an LA
geometry with all its associated potential technical delays that are
absent in the case of PVAC where 3D mapping systems are redun-
dant, simply relying on traditional PV angiography for imaging. In
both the PVAC and WACA groups, there was no pre-specified
waiting time to assess PV reconnection and adenosine testing was
not performed since this had not been verified to be of value in redu-
cing recurrences in randomized controlled trials and still remains
unresolved.17
Complication rates
Therewere also clinically significant differences in complication rates
between the techniques with importantly a 3% tamponade rate, one
delayed presentation of PV stenosis requiring venoplasty in the
WACA group, and 0% tamponade rate but two neurological
events in the PVAC group. The former tamponade events can
most likely be explained by catheter manipulation as opposed to
trans-septal puncture not being guided by TEE, since both tampon-
ade events occurred while the NIH/ablation catheter was being
manipulated in vulnerable areas of the LA after a .10 min period
of unchanged haemodynamic parameters. The steam pop during
lesion delivery in the LA most likely relates to increased pressure
at the roof site as opposed to high power application as the energy
on delivery was limited to 30 W. Although, slightly higher than
some series, this event rate falls into the event rates reported in
the range of 1–6% (http://guidance.nice.org.uk/CG36/Guidance/
pdf/English) from a number of series and is compatible with the
worldwide AF survey data of 1.3% taking into account that this was
registry-based data which can potentially under-report events.18
Furthermore, some of the AF procedures were performed by
experienced clinical fellows under direct Consultant supervision.
This may have contributed to the slightly higher tamponade rate in
conjunction with the use of the steerable Agilis sheath which could
potentially result in higher pressure contact in certain parts of the
atrium especially since the contact force-sensing technology was
not yet available during the study. None of the tamponades required
surgical intervention and promptly responded to direct percutan-
eous drainage.
However, ofmore concern are the two strokeswhichoccurred in
the peri/post-operative period (2% of cases). The first event could
have potentially developed during the procedure or immediately
afterwards, while the second occurred 2 days post-op after transi-
tion from LMWheparin towarfarin. The former case had a previous
history of TIA’s, and although had no evidence of LA thrombus pre-
operatively on TEE with therapeutic ACT’s intra-operatively, it is
conceivable the event was either catheter related (char, coagulum
or air embolisation) or developed as a result of thrombus formation
on the ablation lesions overnight despite post-operative anticoagu-
lation. In a recent meta-analysis of PVAC safety and efficacy, the
incidence of thrombo-embolic complications was 0.63%, with 10
embolic events, that is, 2 strokes, 6TIAs, and2myocardial infarctions
in 1598 patients (23 studies).16 Similar neurological event rateswere
reported in a European voluntary survey of 1.1% in 2848 patients
from 20 centres and of 1.1% in 634 patients in a large single-centre
registry.19,20 Actual neurological events were similar in paroxysmal
and persistent patients and unrelated to case load, bridging anticoa-
gulation to low-molecular weight heparin, sheath flushing average
procedure times or routine use of TEE pre-procedure but the
survey was underpowered to fully examine causes of these
events.19 Two randomized trials comparing PVACwith standard ab-
lationhad no strokes in their respective arms.5,14 This is despite using
lower ACTs of 250–300 s in Bittner et al.’s study. It is possible that
tissue overheating recognized as a problemwith theGENius 11 gen-
erator resulting in its withdrawal in May 2011 could have been an
additional factor promoting char/coagulum formation in the two
stroke cases. Furthermore, it is now becoming evident that stopping
vitamin K antagonists and bridging heparin (undertaken in the 2
PVAC stroke cases) have a higher risk of thrombo-embolic compli-
cations than continuing with oral anticoagulation maintaining thera-
peutic INR’s during the procedure.21,22 Though not specifically a
cause of stroke, it has been recognized that PVAC technology has
been associated with a higher rate of silent cerebral ischaemic
lesions on MRI vs. cooled flow RF most probably due to gas
bubble formation as opposed to thrombus. In a recent porcine
study, microbubble formation was more commonly seen with the
PVAC particularly due to overlap between electrodes 1 and
10 23—this has been confirmed clinically.24,25 In a clinical study,
diffusion-weighted MR cerebral lesion formation was minimized
using a combination of optimal sheath management to prevent the
introduction of air into the LA, full heparinization in warfarinized
patients, and avoidance of electrode 1–10 contact.26 Avoidance of
the latter reduced cerebral lesion formation four-fold. The ERACE
trial has confirmed that these interventions significantly reduce
the asymptomatic cerebral emboli incidence to 1.7%.27 These
factors were not identified during the ablation phase of the trial.
However, it is difficult to knowwhether they would have prevented
the peri-procedural stroke and are unlikely to have changed the
outcome in the later post-procedural event which is more likely
related to thrombus formation in the hypercoaguable state during
transition from LMW heparin to warfarin.
Safety and efficacy of multipolar PVAC 1151
 at U
CL Library Services on Septem
ber 10, 2014
http://europace.oxfordjournals.org/
D
ow
nloaded from
 
There have been concerns regarding the incidence of PV stenosis
using the PVAC.28 This study did not search systematically for PV
stenosis and only imaged the PV’s in patients undergoing repeat abla-
tionor symptomatic PV stenosis causing exertional breathlessness or
haemoptysis. Therefore, we may have underestimated its incidence.
In a recent prospective study of 100 PVAC cases, cardiac MR/com-
puted tomography (CT) imaging demonstrated a detectable narrow-
ingof thePVdiameter in 23patients and in 28 (7%)PVs.29 Insignificant
PV stenosis (,25%) was observed in 12 (2.9%) PVs, mild PV (25–
50%) stenosis in 15 PVs (3.7%), and moderate PV stenosis (50–
75%) in 1 PV (0.2%). No instances of severe PV stenosis were
observed. This suggests that although caution should be applied,
the incidence of clinically important PVAC induced PV stenosis is
low. The delayed PV stenosis in the WACA patient arose due to in-
advertent ablation near the PV ostium due to geometry shift. This
highlights the importance of ensuring geometry stability and utilizing
fluoroscopy to confirm catheter location.
Recurrence of PAF at 12 months
The lack of a significant difference between recurrence rates in the
PVAC and WACA arms despite achieving PV isolation is interesting
and reflects the limitations of current ablation strategies for PAF in
achieving durable PV isolation. The endpoint of PV isolationwas con-
fidently achieved during WACA and tested using differential pacing
with PVAC ablation and yet reconnection occurred at the same
rate even though RF times were shorter in the PVAC group.
Indeed, the WACA RF times are substantially shorter than that
reported by Bittner, et al. (35 vs. 65 min) and yet the recurrence
rates in this group are equivalent.5 However, there is the caveat
that the latter study combined paroxysmal and persistent cases al-
though no additional linear/atrial body ablation was performed.
This must reflect the fact that these technologies are unable to
deliver adequate transmural permanent lesions or there is a capacity
for the PVs to reconnect perhaps by the re-growth of epicardial
venous muscle sleeves. Inherent in the process of RF lesion delivery
is thedevelopmentofoedemawhichmay result in transient lossof PV
connection.27 Current efforts are focused upon delivering lesions
with optimal contact force to minimize this problem and the
imaging of lesion formation to ensure trans-murality.30 However,
one must bear in mind that although PV reconnection is a very
likely the cause of recurrence, up to 30% of PV’s reconnections
may be clinically silent.31 Inherent in this process is the need to
deliver the optimum energy to achieve permanent PV isolation
without excessive tissue injury resulting in tamponade, oesophageal
injury, or PV stenosis. This problem may be addressed in future by
design changes with the PVAC GOLD and new GENius generator
which may lead to desired improvements in durable PV lesions.
The evolution of irrigated multipolar RF delivery systems (e.g.
-n-MARQ, Biosense-Webster) would be expected to also minimize
the formation of thrombo-embolic material during RF delivery;
however, preliminary reports suggest that theremaybe anunexpect-
edly high incidence of silent cerebral emboli and oesophageal injury
with this technology.32 All these systems should ideally monitor
lesion formation and contact force to maximize the probability of
permanent transmural lesion creation.
Comparisonwithother trials ofpulmonary
vein ablation catheter in PAF
Six studies have directly compared PVAC with 3D-guided RF abla-
tion. However, only two have done so in a randomized fashion
with one examining the importance of PV anatomy.5,8–14 Bulava
et al.14 randomized 102 patients. After a mean follow-up of 200+
13 days, freedom from recurrent AF in patients off AADs was 71%
(36 of 51) vs. 67% (34 of 51), respectively. Bittner et al.5 randomized
80 consecutive patients with PAF (55%) or persistent AF (45%) to
PVAC-based or conventional 3D-based RF ablation. After a mean
follow-up of 254+ 99 days, freedom from recurrent AF off AADs
was 58% (23 of 40) vs. 43% (17 of 40), respectively. Although well
conducted, both studies did not report follow-up at a fixed cut-off
of 12 months and in the latter study, a mixed population is
described which confounds interpretation of the results to a
degree. However, the outcomes at the 9-month time point are
equivalent to the data reported in this trial. Overall, our results
reflect the pooled estimate of 12 m freedom from AF after PVAC
of 52–67%, the wide 95% confidence intervals representing the het-
erogeneity of the study populations and outcomes, (http://guidance.
nice.org.uk/CG36/Guidance/pdf/English) althoughonly three studies
have reported 12-month follow-up data.9,10,33 These data are also
similar to a European survey in which 20 centres reported outcomes
in 1669 PAF cases with a 59% success rate of anti-dysrhythmic
medication.19
Study limitations
A limitationof this studywas the lackof prospective evaluation for PV
stenosis in both theWACAand PVAC groups and so no firm conclu-
sions can be drawn regarding the incidence of subclinical PV stenosis.
This would have required routine CT, MRI, or TEE scanning at
6 months post-procedure. Data were only collected in cases under-
going repeat procedures.34 There was no prospective performance
of cerebral MRI scans for microemeboli as this issue only came to
light in the follow-up phase of the study and so it was not possible
to undertake such a prospective analysis.
Conclusions
This multicentre randomized controlled trial demonstrates that
PVAC PV isolation is equivalent in efficacy to WACA with clinically
significantly shorter procedure times for PAF ablation. The challenge
still remains to achieve durable efficacy of PAF ablation with the
minimum of complications and ensure that new technologies are
rigorously evaluated in a randomized fashion with clearly defined
long-term clinical endpoints.34 The avoidance of irreversible debili-
tating complications such as cerebrovascular accident (CVA) is crit-
ical in this endeavour with prospective evaluation of preventative
interventions in large cohorts to ensure they are effective.
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